准分子激光上皮下角膜磨镶术后应用0.5％氯替泼诺混悬滴眼液的临床分析

目的:观察准分子激光上皮下角膜磨镶术(laser epithelial keratomileusis,LASEK)术后应用0.5％氯替泼诺混悬滴眼液的临床效果,包括角膜上皮下雾状混浊(Haze)、眼压增高发生情况.方法:总计接受LASEK患者176例345眼,分为试验组84例165眼,术后应用0.5％氯替泼诺混悬滴眼液患者,对照组92例180眼,术后应用0.1％氟米龙滴眼液患者,观察术后6个月时Haze发生率、6个月内眼压增高的发生率,采用x2检验进行统计学分析.结果:试验组与对照组6个月时术后Haze发生率分别为9.70％(16眼)和17.22％(31眼),两者差异有统计学意义(P＜0.05)；术后6个月内眼压增高发生率分别为3.64％(6眼)和10.00％(18眼),两者差异有统计学意义(P＜0.05).结论:与0.1％氟米龙滴眼液相比,LASEK术后应用0.5％氯替泼诺混悬滴眼液引起眼压增高的发生率明显降低,可有效预防Haze发生,临床效果安全有效.

Clinical analysis of 0.5% loteprednol etabonate ophthalmic suspension after laser epithelial keratomileusis

Objectivev To observe the clinical effect of 0.5% loteprednol etabonate ophthalmic suspension after laser epithelial keratomileusis(LASEK), including subepithelial Haze, high intraocular pressure(IOP). Methods All 345 eyes were divided to 165 eyes with 0.5% loteprednol etabonate in the experimental group and 180 eyes with 0.1% fluorometholone in the control group. Observed and compared the incidence of Haze and IOP in 6 months postoperative. Results The incidences of Haze were significantly different (P < 0.05) between the experimental group (9.70%) and control group (17.22%), so were those of high IOP between the experimental group (3.64%) and control group (10.00%). Conclusions Compared with traditional steroid suspension, 0.5% loteprednol etabonate ophthalmic suspension can significantly reduce occurrence of high IOP and Haze. It could be a safe and effective drug-using after LASEK.